Table 2.

Change from baseline in patient-reported numerical reporting scale scores at week 4

Statistic	Orvepitant 30 mg n=16	Orvepitant 10 mg n=14	Placebo n=14
n	13	11	14
Mean (SD)	−2.78 (2.64)	−3.04 (3.06)	−3.21 (1.77)
Median	−2.75	−2.00	−2.50
Minimum, maximum	−6.3 to 3.0	−8.3 to 1.1	−6.3 to 0.0
LSMEANS estimate (95% CI)	−2.40 (−3.54 to −1.27)	−2.53 (−3.80 to −1.27)	−3.70 (−4.88 to −2.52)
LSMEANS SE	0.56	0.62	0.58
Orvepitant versus placebo difference (95% CI)	1.30 (−0.35 to 2.95)	1.17 (−0.62 to 2.96)
P value	0.120	0.194

Analysis results from mixed-model repeated measures analysis (week 1 to week 4) of the three treatment groups analysed together in one model: change from baseline=treatment+pooled site+visit+treatment*visit+baseline results+visit*baseline covariate interaction.

LSMEANS, least-squares means.